苯海拉明和地氯雷他定的功效和安慰剂的患者严重的季节性过敏性鼻炎。

文章的细节

引用

复制到剪贴板

拉斐尔GD Angello JT,吴MM, Druce嗯

苯海拉明和地氯雷他定的功效和安慰剂的患者严重的季节性过敏性鼻炎。

安过敏哮喘Immunol。2006年4月,96(4):606 - 14所示。

PubMed ID

16680933 (在PubMed

]

文摘

背景:先前的研究已经表明,苯海拉明和地氯雷他定有效减轻季节性过敏性鼻炎的症状(SAR)。目的:比较的相对有效性50毫克盐酸苯海拉明、5毫克的地氯雷他定,和安慰剂的患者缓解症状严重SAR。方法:在这一周,多中心,与这些相应平行的组织,随机、双盲、double-dummy,安慰剂对照研究中,610名患有严重SAR收到50毫克盐酸苯海拉明每天3次,一次5毫克的地氯雷他定,或安慰剂。每日24小时反射全部鼻症状评分(评分)(主要终点),总症状评分,和个人症状评分进行评估。全球评估对治疗的反应是由2治疗后的访问。结果:基线的减少意味着24小时反射从而相对于安慰剂反应是苯海拉明组为77.6% (P <措施)和21.0%的地氯雷他定组(P =点)。一个评分之间差异-1.81 (46.7%;观察P <措施)当比较苯海拉明和地氯雷他定。类似的处理间差异是24小时观察反光症状总分比较苯海拉明和地氯雷他定(-3.35;45.5%;P <措施)。 Diphenhydramine provided clinically and statistically significant reductions vs placebo and desloratadine in all individual symptoms, including nasal congestion. Desloratadine had a tendency toward improvement compared with placebo for most individual symptom scores. However, a statistically significant result was reached only for sneezing (-0.27; 33.9%; P = .04). CONCLUSIONS: Diphenhydramine, 50 mg, given for 1 week provided statistically significant and clinically superior improvements in symptoms compared with 5 mg of desloratadine in patients with moderate-to-severe SAR. Somnolence occurred more frequently with diphenhydramine (22.1%) compared with desloratadine (4.5%) and placebo (3.4%).

DrugBank数据引用了这篇文章

药物

苯那君